Using our unique cancer-specific data set containing 23+ different
types of cancers with over 70,000 relevant patients’ prognosis data,
we can help pharmaceutical companies developing anti-cancer
drugs to select the most appropriate cancer types for a given anti-cancer agent.
Phamaceutical companies can better able to identify the specific
cancer market, design clinical trials to improve the success rate of
clinical approval, and manage pipeline strategy.
Carcinoma of Unknown Primary
Carcinoma of Unknown Primary (CUP) is a diverse group of
cancers that is defined by the presence of metastatic disease
with no identified primary tumor at initial presentation.
CUP is reported to comprise approximately 2% to 5% of all
cancer cases and conventional immunohistochemical staining
methods can only find 70% of the primary site of CUP.
ONCOfind AI can identify the primary site of CUP with 99%
accuracy with proprietary transcriptomic dataset of over
70,000 cancer patients of multiple races and 40 main types of
cancers with 79 subtype with various phenotype information.
Pharmaceutical companies spend billions of dollars in the early
stages of drug discovery to get to a single lead compound opti-
mization. Using our drug and disease data set, we can screen
additional indications for drug compounds that are in the
preclinical stage in the Phase I clinical trials. Subsequently,
the screened new or additional indications can begin Phase
II or Phase I / IIa clinical trials directly.
Pharmaceutical companies can increase the value of the drug
compound under development by adding additional pipeline
without spending billions of dollars in many years.
New drug compounds typically have approximately 86%
failure rates during clinical trials. We screen to find a new
indication for drug compounds that have failed in Phase II
or III clinical trials, thus, failed to show efficacy for the
originally targeted indication. Since the compound has
been tested for toxicity by passing Phase I clinical trial,
we can conduct preclinical efficacy test only and directly
begin Phase II clinical trial.
Pharmaceutical companies can save, on average, 95% of
the cost and 7 years in time from the compound discovery
stage to Phase I clinical trials.
Incrementally Modified Drug
We take marketed drugs to select the most suitable combination
of two or more drugs by changing the formulation or chemical
structure to improve the delivery speed, safety, and efficacy of
Compared to the conventional new drug development process,
it costs less and can be developed faster while reducing the
clinical trial risks.
There are over 7,000 rare diseases worldwide and less than
only 6% of the disease have approved treatment.
Using our proprietary transcriptomic patients data, drug
data, and disease data with 19+ rare disease cohorts, we
can screen and repurpose existing marketed drugs with
known pharmacokinetics and pharmacodynamics to find
the solution for rare disease.
Pandemic situation like COVID-19 requires rapid development
of vaccines or new drugs, especially when the disease is prone
to mutation. Up until now, there is no established treatment
for COVID-19, so other types of antiviral drugs for AIDS or Flu
has been administered. However, we can still see cytokine
storm in some patients even when the viral load decreases.
Given the merits of AI technology's speed and accuracy, we
can effectively screen to develop the optimal combination
therapy that can improve the symptoms while suppressing
We are currently collaborating with Korea’s Infectious Disease
Department, University Hospital, and Korea Institute of
Bioscience and Biotechnology in an effort to find the